设为首页 加入收藏

TOP

Nplate 250 micrograms powder and solvent for solution forinj
2013-11-12 23:58:25 来源: 作者: 【 】 浏览:396次 评论:0

For doctors

 

What is it and how is it used?

Nplate’s active ingredient is romiplostim, which is a protein used to treat low platelet counts in patients with immune (idiopathic) thrombocytopenic purpura (called ITP). ITP is a disease in which your body’s immune system destroys its own platelets. Platelets are the cells in your blood that help seal cuts and form blood clots. Very low platelet counts can cause bruising and serious bleeding.

Nplate is used to treat adult patients (aged 18 years and over) who have had their spleen removed for chronic ITP and who have been previously treated with corticosteroids or immunoglobulins, where these treatments don’t work.

Nplate may also be used in previously treated adult patients (aged 18 years and over) with chronic ITP in whom surgery is not an option.

Nplate works by stimulating the bone marrow (part of the bone which makes blood cells) to produce more platelets. This should help to prevent bruising and bleeding associated with ITP.

What do you have to consider before using it?

DO NOT use Nplate

Take special care with Nplate

If you have very high blood platelet counts this may increase the risk of blood clotting. Your doctor will adjust your dose of Nplate to ensure that your platelet count does not become too high.

Bone marrow changes (increased reticulin and possible bone marrow fibrosis)

Long-term use of Nplate may cause changes in your bone marrow. These changes may lead to abnormal blood cells or your body making less blood cells. The mild form of these bone marrow changes is called “increased reticulin” and has been observed in Nplate clinical trials. It is not known if this may progress to a more severe form called “fibrosis.” Signs of bone marrow changes may show up as abnormalities in your blood tests. Your doctor will decide if abnormal blood tests mean that you should have bone marrow tests or if you should stop taking Nplate.

Worsening of blood cancers

Your doctor may decide to take a bone marrow biopsy if they decide it is necessary to ensure that you have ITP, and not another condition such as MDS.

Loss of response to romiplostim

If you experience a loss of response or failure to maintain a platelet response with romiplostim treatment, you doctor will investigate the reasons why including whether you are experiencing increased bone marrow fibres (reticulin) or have developed antibodies which neutralise romiplostim’s activity.

Nplate is not recommended for use in children below age 18.

Using other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

If you are also taking medicines which prevent blood clots (anticoagulants or antiplatelet therapy) there is a greater risk of bleeding. Your doctor will discuss this with you.

If you are taking corticosteroids, danazol, and/or azathioprine, which you may be receiving to treat your ITP, these may be reduced or stopped when given together with Nplate.

Pregnancy and breast-feeding

It is important to tell your doctor if you are pregnant; think you may be pregnant; or plan to get pregnant. Nplate is not recommended for use if you are pregnant unless indicated by your doctor.

It is not known whether romiplostim is present in human milk. Nplate is not recommended for use if you are breast-feeding. A decision on whether to discontinue breast-feeding or discontinue therapy with romiplostim should be made taking into account the benefit of breast-feeding to your child and the benefit of romiplostim therapy to you.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed. You should speak with your doctor before driving or using machines, as some side effects (e.g., temporary bouts of dizziness) may impair your ability to do so safely.

How is it used?

Nplate will be given under the direct supervision of your doctor, who will closely control the amount of Nplate given to you.

Nplate is administered once a week as an injection under the skin (subcutaneous).

Your initial dose is 1 microgram of Nplate per kilogram of your body weight once a week. Your doctor will tell you how much you must take. Nplate should be injected once per week in order to keep your platelet counts up. Your doctor will take regular blood samples to measure how your platelets are responding and may adjust your dose as necessary.

Once your platelet count is under control, your doctor will continue to regularly check your blood. Your dose may be adjusted further in order to maintain long-term control of your platelet count.

If you use more Nplate than you should

Your doctor will ensure that you receive the right amount of Nplate. If you have been given more Nplate than you should, you may not experience any physical symptoms but your blood platelet counts may rise to very high levels and this may increase the risk of blood clotting. Therefore if your doctor suspects that you have been given more Nplate than you should, it is recommended that you are monitored for any signs or symptoms of side effects and that you are given appropriate treatment immediately.

If you forget to use Nplate

If you have missed a dose of Nplate, your doctor will discuss with you when you should have your next dose.

If you stop using Nplate

If you stop using Nplate, your low blood platelet count (thrombocytopenia) is likely to reoccur. Your doctor will decide if you should stop using Nplate.

What are possible side effects?

Like all medicines, Nplate can cause side effects, although not everybody gets them.

Very common side effects (seen in more than 1 in 10 people taking Nplate):

Common side effects (seen in more than 1 in 100 people taking Nplate):

Uncommon side effects (seen in more than 1 in 1000 people taking Nplate):

Uncommon side effects that may show up in blood or urine tests (seen in more than 1 in 1000 people taking Nplate):

Other side effects:
A rare disorder characterised by periods of burning pain, redness and warmth in the feet and hands (erythromelalgia).

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Nplate after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2° C – 8° C).
Do not freeze.
Store in the original carton in order to protect from light.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

Nplate is a powder that is made up into a solution for injection. Nplate is available with or without a solvent. It contains the active substance romiplostim.

What is it used for?

Nplate is used in adults with long-term immune thrombocytopenic purpura (ITP), a disease in which the patient’s immune system destroys the platelets (components in the blood that help it to clot). Patients with ITP have low platelet counts and are at risk of bleeding.
Nplate is used in patients who have already been treated with medicines such as corticosteroids or immunoglobulins and who have had their spleen removed, if these treatments have not worked. It can also be considered for use in patients who have been treated for ITP who have a spleen and cannot have surgery. The spleen is an organ that is involved in the destruction of platelets. Because the number of patients with ITP is low, the disease is considered ‘rare’, and Nplate was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 27 May 2005. The medicine can only be obtained with a prescription.

How is it used?

Treatment with Nplate should be supervised by a doctor who has experience in treating blood diseases.
Nplate is given once a week as an injection under the skin. The starting dose depends on the patient’s weight, and is then adjusted every week to maintain platelet counts at target levels. Treatment can be interrupted if platelet counts become too high. Treatment with Nplate should be stopped after four weeks of treatment with the maximum dose of Nplate if the platelet count does not reach levels that are high enough to reduce the risk of bleeding.

How does it work?

The active substance in Nplate, romiplostim, is a medicine that stimulates the production of platelets. In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets in the bone marrow. Romiplostim is a protein that has been ‘engineered’ (specifically designed) so that it can attach to and stimulate the same receptors as thrombopoietin. By mimicking the action of thrombopoietin, romiplostim stimulates the production of platelets, increasing blood platelet counts.

Romiplostim is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce romiplostim.

How has it been studied?

Nplate has been compared with placebo (a dummy treatment) in two main studies involving adults with long-term ITP. The first study involved 63 patients whose spleens had been removed but whose disease was still not controlled. The second study involved 62 patients who still had their spleens and who had been treated for ITP in the past.
In both studies, the main measure of effectiveness was the number of patients who had a lasting response to treatment. This was classified as the patient’s platelet counts being above 50 million per millilitre for at least six of the last eight weeks of the 24-week treatment period, without the need for any other medicines for ITP. Platelet counts below 30 million per millilitre are considered to put ITP patients at risk of bleeding, while normal counts are between 150 and 400 million per millilitre.

What benefits has it shown during the studies?

Nplate was more effective than placebo at increasing blood platelet counts. In the study of patients whose spleen had been removed, 38% of the patients had a lasting response to treatment with Nplate (16 out of 42), compared with none of the 21 patients receiving placebo. In the study of patients with a spleen, 61% of the patients had a lasting response to treatment with Nplate (25 out of 41), compared with 5% of the patients receiving placebo (1 out of 21).

What is the risk associated?

The most common side effect with Nplate (seen in more than 1 patient in 10) is headache. For the full list of all side effects reported with Nplate, see the Package Leaflet.
Nplate should not be used in people who may be hypersensitive (allergic) to romiplostim, any of the other ingredients, or proteins produced by Escherichia coli (a bacterium).

Why has it been approved?

The Committee for Medicinal Products for Human Use (CHMP) noted that the effectiveness of Nplate had been shown in patients whose spleens had been removed, as well as in patients who still had their spleens. However, because removal of the spleen is a potential cure for ITP, the Committee concluded that Nplate should only be used in patients with a spleen if they are not able to undergo surgery. The CHMP decided that Nplate’s benefits are greater than its risks and recommended that it be given marketing authorisation.

How has it been studied?

The company that makes Nplate will provide educational packs for doctors in each Member State. The packs will include information on the safety and effectiveness of Nplate. They will also remind doctors how to use the medicine and to discuss the benefits and risks of Nplate with patients. Doctors will also receive a ‘dosing calculator’ to help them calculate the volumes of Nplate that need to be injected. These volumes can sometimes be very small.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Nplate to Amgen Europe B.V. on 4 February 2009. The marketing authorisation is valid for five years, after which it can be renewed.

The summary of the opinion of the Committee for Orphan Medicinal Products for Nplate is available here.

↑ back to table of contents ↑

Name

Nplate 250 micrograms powder and solvent for solution for
injection

Composition

Each vial contains 250 µg of romiplostim. After reconstitution, a deliverable volume of 0.5 ml solution contains 250 µg of romiplostim (500 µg/ml). An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered.

Romiplostim is produced by recombinant DNA technology in Escherichia coli ( E. coli).

For a full list of excipients, see section 6.1.

Pharmaceutical Form

Powder and solvent for solution for injection.

The powder is white.
The solvent is a clear colourless liquid.

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Nplate 250 micrograms powder fo.. 下一篇Nplate 500 micrograms powder an..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位